A novel nanomissile targeting two biomarkers and accurately bombing CTCs with doxorubicin
- 30 March 2017
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 9 (17) , 5624-5640
Abstract
Rare circulating tumor cells (CTCs) cause >50% of primary colorectal cancer survivors to develop deadly metastasis at 3–5 years after surgery; the current chemotherapies can do nothing about these cells. Herein, we synthesized a novel doxorubicin (DOX)-entrapped mesoporous silica nanoparticle (MSN), covalently-conjugated with two aptamers, for simultaneously targeting EpCAM and CD44, the typical surface biomarkers of colorectal CTCs. The nanomissile can specifically capture the metastasis-prone CTCs spiked in healthy human blood in a competitive-binding manner. The binding not only accurately delivers DOX into the cancer cells via the biomarker-mediated endocytosis to inhibit CTC viability through the DOX-dependent mechanism, but also inhibits the adhesion of cancer cells to the endothelium and the consequent transmembrane migration through the DOX-independent mechanism. The molecular entity of the conjugate and its pharmaceutical DOX encapsulation-releasing capacity are well-demonstrated via various physiochemical characterizations including gel electrophoresis, which proves the >8-hour biostability of the nanomissile in blood, long enough for it to chase CTCs in mice and synergistically inhibit the CTC-induced lung metastasis more potently than its single aptamer-conjugated counterparts and DOX itself. The present strategy may pave a new avenue for safe and effective cancer metastasis chemoprevention.Keywords
Funding Information
- Natural Science Foundation of Fujian Province (2016J06020)
This publication has 64 references indexed in Scilit:
- The Architecture and Function of Monoclonal Antibody‐Functionalized Mesoporous Silica Nanoparticles Loaded with Mifepristone: Repurposing Abortifacient for Cancer Metastatic ChemopreventionSmall, 2016
- Cancer‐Cell‐Specific Nuclear‐Targeted Drug Delivery by Dual‐Ligand‐Modified Mesoporous Silica NanoparticlesSmall, 2015
- Isolation and characterization of living circulating tumor cells in patients by immunomagnetic negative enrichment coupled with flow cytometryCancer, 2015
- Enhanced Specificity in Capturing and Restraining Circulating Tumor Cells with Dual Antibody–Dendrimer ConjugatesAdvanced Functional Materials, 2015
- Aptamers as Drug Delivery VehiclesChemMedChem, 2014
- Postoperative Detection of Circulating Tumor Cells Predicts Tumor Recurrence in Colorectal Cancer PatientsJournal of Gastrointestinal Surgery, 2013
- Cell‐based selection provides novel molecular probes for cancer stem cellsInternational Journal of Cancer, 2012
- Circulating Tumor Cells (CTCs) Detected by Triple-Marker EpCAM, CK19, and hMAM RT-PCR and Their Relation to Clinical Outcome in Metastatic Breast Cancer PatientsCell Biochemistry and Biophysics, 2012
- Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCRBreast Cancer Research and Treatment, 2008
- Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamilJournal of Cancer Research and Clinical Oncology, 1997